StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Zetia (ezetimibe, legacy pre-Organon spin-off) by Quarter

Zetia (ezetimibe, legacy pre-Organon spin-off) — International sales ($M) ($M)

QuarterlyAnnual

Merck Zetia (ezetimibe, legacy pre-Organon spin-off): $90M in Q1 2021, down 38.8% from a year earlier. That is the lowest of the 18 quarters on record here. No newer figure appears in the documents we track.

Latest, Q1 2021
90
Period ended Mar 31, 2021
Change on a year earlier
-38.8%
147 in Q1 2020
History
18 quarters
Since Q4 2016
Sources
13
Documents cited below

Where the Q1 2021 figure comes from

“|| Zetia | 92 | 145 | -37 | 2 | (2 | ) | -199 | 90 | 147 | -39”

Source: Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZetia (ezetimibe, legacy pre-Organon spin-off) — International sales ($M) ($M)Year on yearSource
Q1 2021Mar 31, 202190-38.8%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2020Dec 31, 202094-34.7%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 2020103-27.5%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 2020138-8.0%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 2020147+5.0%Form 8-K (tm2114316d1_ex99-1.htm, filed 2021-04-29) ↗
Q4 2019Dec 31, 2019144-4.6%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 2019142-9.6%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 2019150-31.2%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 2019140-51.2%Form 10-Q (filed 2020-05-06) ↗
Q4 2018Dec 31, 2018151-43.9%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 2018157-38.4%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2018Jun 30, 2018218-11.4%Form 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2018Mar 31, 2018287+29.3%Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗
Q4 2017Dec 31, 2017269+12.1%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 2017255–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 2017246–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗

Breakdown

What makes up zetia (ezetimibe, legacy pre-Organon spin-off)

Cite this data

StockData. (2026). Merck Zetia (ezetimibe, legacy pre-Organon spin-off) ($M), quarterly Q4 2016–Q1 2021 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zetia-intl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.